Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib (HM43239) for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose Expands Senior Leadership Team

Oct 25, 2021 8:00am EDT

Aptose to Present at September Investor Conferences

Aug 30, 2021 7:30am EDT

Aptose Reports Results for the Second Quarter 2021

Aug 03, 2021 4:01pm EDT

Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021

Jul 20, 2021 4:01pm EDT

Aptose Presents Highlights from EHA During Corporate Update Event

Jun 11, 2021 7:55am EDT

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

Jun 01, 2021 4:30pm EDT

Aptose to Hold Corporate Update Friday, June 11th

May 27, 2021 7:30am EDT

Aptose to Present at Upcoming Investor Conferences

May 12, 2021 7:30am EDT

Aptose Reports Results for the First Quarter 2021

May 04, 2021 4:01pm EDT

Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021

Apr 26, 2021 4:02pm EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...25
    Next
    © 2023 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap